Symptom suppression in subjects with perennial allergic rhinitis treated with mometasone furoate nasal spray.
Allergic rhinitis (AR) carries a high symptom burden and impact on quality of life. The ability of an AR treatment to achieve and sustain symptom suppression would be expected to enhance quality of life and improve long-term outcomes. In this ad hoc analysis of data from 4 phase 3 clinical trials of mometasone furoate nasal spray (MFNS), subjects with perennial AR recorded the severity of nasal symptoms twice daily for 12 weeks on a 4-point scale to determine the total nasal symptom score. In the pooled sample of 1,149 subjects, 580 received MFNS 200 μg per day and 569 received placebo. Significantly more subjects receiving MFNS achieved symptom suppression versus those receiving placebo: 63.3% (n = 367) versus 51.0% (n = 290; p < 0.001). Median time to suppression was significantly shorter with MFNS versus placebo (29 vs. 59 days; p < 0.001). Total suppression was achieved in a significantly greater percentage of patients receiving MFNS versus placebo (36.0 vs. 25.5%; p < 0.001). A high level of symptom relief is attained faster and sustained longer with MFNS. This analysis validates the importance of treatment adherence to achieve optimal, sustained symptom relief.